RSS

Merck Strengthens Presence as Leading Oncology Company by Taking Full Promotional Responsibility for Erbitux in JapanFerbuary 13, 2015

Merck and Bristol-Myers Squibb to end co-promotion of Erbitux in Japan, with full promotional responsibilities transferring to Merck

Darmstadt, Germany, February 13, 2015 – Merck, a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials, today announced that Merck and Bristol-Myers Squibb have agreed to transfer full responsibility for the promotion of Erbitux® (cetuximab) to Merck in Japan as of May 1, 2015.

Belén Garijo, Member of the Executive Board of Merck and CEO Healthcare

Belén Garijo, Member of the Executive Board of Merck and CEO Healthcare

“Expanding our oncology presence in Japan is of strategic importance to achieve our long term ambition to become a leading global player in oncology and immuno-oncology,” said Belén Garijo, Member of the Executive Board of Merck and CEO Healthcare.

The transfer of promotional responsibilities for Erbitux in Japan further increases Merck’s presence in this important strategic market, where the company has already positioned Japan as its regional Research and Development hub for North East Asia.

Elcin Ergun, Head of Global Commercial at Merck Serono

Elcin Ergun, Head of Global Commercial at Merck Serono

“With this agreement, Japan will increasingly become a key focus country for us as it complements our Asia-centric Research and Development strategies. As a result, we plan to work diligently to develop therapies that best suit the unmet need, and the epidemiological profiles of Asian patient populations,” said Elcin Ergun, Head of Global Commercial at Merck Serono, the biopharmaceutical business of Merck.

Erbitux was launched in collaboration with Bristol-Myers Squibb in Japan in September 2008 for the treatment of metastatic colorectal cancer, followed by an additional indication for the treatment of head and neck cancer, approved in December 2012.*

* Please refer to the local prescribing and product information for details.

 
Leave a comment

Posted by on February 18, 2015 in Industry

 

Merck Serono to take back all responsibility for diabetes and thyroid brands in Russia

  • Expanding our General Medicines and Cardiometabolic Care business by targeting the increasing healthcare needs in Russia
  • Transition of responsibilities from Takeda-effective 1 January 2015

Merck Serono has repatriated all responsibility for our diabetes and thyroid brands in Russia from our commercial partner Takeda. Up to 31 December 2014, Takeda ran all promotional, marketing, and distributional activities on these products. From now on, a newly created dedicated sales and marketing team in our Russian affiliate will handle marketing and promotion in Russia.

The decision forms part of our strategic commercial focus on emerging markets, one out of three key pillars of Merck Serono’s strategy for growth:

  • Innovate globally: Globally we will deliver innovation and best in class launches in Oncology (TH-302), Immuno-oncology (anti-PD-L1), Immunology (atacicept).
  • Maximize our base portfolio: We will maximize our existing drugs and related devices and services: Rebif®, Erbitux®, Gonal-f®
  • Expand in emerging markets: In emerging markets we will expand by building on growth initiatives in our General Medicine and Specialty Care franchises, and by harnessing innovation, manufacturing and supply solutions locally.

Where there are opportunities to do so, we will look to enhance our operations and drive growth in emerging markets, including taking back part of responsibilities, or all of them where appropriate. In 2013, Merck Serono and Bristol-Myers Squibb (BMS) signed an agreement to co-promote Glucophage® in China to help increase treatment for the growing number of patients in China with Type 2 diabetes. Prior to this, BMS marketed Glucophage in China starting in 1999 pursuant to a license from Merck Sante.

Regarding this new decision, transferring back responsibility for the products of the Glucophage and Euthyrox family in Russia, Susan Herbert, Head of Global Business Development & Alliance Management at Merck Serono said: ““Through this repatriation approach, we expect to expand the geographic distribution of Glucophage and Euthyrox with the goal of increasing their accessibility for patients. Together with our partners in commercial, Global Business Development will continue to look for opportunities amongst our existing brands and products to build on this approach.”

In 2014, we expanded our retail sales channel in Russia, increasing our local sales force and upgrading it to a fully-fledged entity. The creation of a dedicated sales and marketing team will help us to reach out to more people in urban and rural communities who may currently be experiencing difficulty in accessing high quality medicines.

Elcin Ergun, Head of Global Commercial at Merck Serono

Elcin Ergun, Head of Global Commercial at Merck Serono

Elcin Ergun, Head of Global Commercial at Merck Serono commented: “Repatriation of our products used in the treatment of diabetes and thyroid disorders is well aligned with our commercial priorities in Emerging Markets, especially in strategic markets like Russia. Where opportunities arise, we will seek to bring marketing, and sales activities back ‘in house’ to support business growth and foster further market development through increased diagnosis and access. This decision also reflects our commitment to patients and society in Russia. We will continue to strengthen our business by expanding our commercial footprint, as well as by harnessing manufacturing and supply solutions locally. This was exemplified by our recent announcement of our strategic collaboration with Pharmstandard on local fill and finish production, marketing and distribution of Merck’s Rebif, for Multiple Sclerosis treatment in Russia. Providing access to the best therapies for patients is the overriding priority for our business.”

Diabetes and thyroid brands including Glucophage (metformin hydrochloride), and Glucophage XR®, Glucovance® (metformin and glibenclamide), Euthyrox® (levothyroxine sodium), Jodid® (potassium iodide; IodbalanceTM in Russia), and Thyrozol® (thiamazole) will now transfer all functions over to Merck Serono. Takeda will continue to market our Concor® and other General Medicine products in Russia. In other CIS countries as well as Georgia, Mongolia, Turkmenistan and Ukraine, Takeda will continue to commercialize all products in our portfolio for the treatment of diabetes, cardiovascular diseases and thyroid disorders alongside other General Medicine products.

François Feig, Head of the Global Business Franchise General Medicine & Endocrinology at Merck Serono said: “Our diabetes and thyroids brands are already well established and regarded by doctors and patients in Russia. Merck Serono is making a statement of intent through these changes – helping deliver top-quality therapies to those in need in Russia by capitalising on decades of experience that made Glucophage the diabetes brand with the largest number of patients in the world.”

 
Leave a comment

Posted by on February 18, 2015 in Industry

 

Merck Inaugurates Biomass Plant in Goa, India

  • Co-generation unit promotes climate protection and energy efficiency
  • To manufacture vitamin preparations, industrial and laboratory chemicals as well as microbiological products, among others

Goa/Mumbai, November 25, 2014 – Merck, a leading company for innovative and top-quality high-tech products in the pharmaceutical, chemical and life science sectors, today commissioned a climate-neutral co-generation plant at its production site in Goa, India.

Goa

In doing so, Merck is underscoring its commitment to climate protection and energy efficiency in line with its corporate responsibility. The project is part of a company-wide climate protection program. Merck previously commissioned a new co-generation plant at its headquarters in Darmstadt in July.

Thierry Hulot

Dr. Thierry Hulot, Executive Vice President, Head of Global Manufacturing & Supply
and Member of Merck Pharmaceutical Executive Committee

Dr. Thierry Hulot, Executive Vice President, Head of Global Manufacturing & Supply and Member of Merck Pharmaceutical Executive Committee visited India on the occasion and inaugurated the plant. He said, “Merck’s new climate-neutral co-generation plant in Goa has a tremendous power output for our pharmaceutical and chemical production operations. In the manufacture of our products, we seek to impact the environment as little as possible. As a responsible company, we express our respect to the environment in an Industrial Plant that provides medicines for millions of patients in India.”

Merck’s Goa site is located in Usgao, around 45 kilometers from Panaji, the capital of the Indian state of Goa. This co-generation unit, which has a power output of three megawatts, generates electricity and steam for the pharmaceutical and chemical production operations in Goa. Merck is mainly recycling the shells of cashews and coconuts, two crops that are farmed in the region, to use as biomass. Overall, this will make it possible to reduce carbon dioxide emissions by around 11,500 metrics tons, corresponding to around 85% of the site’s total CO2 emissions. The biomass plant, which represents an investment of more than € 3 million, will ensure that the site has a reliable supply of energy and can operate independently of the public power grid. More than 300 employees manufacture vitamin preparations, industrial and laboratory chemicals as well as microbiological products, among other things.

Mr. Pramod Pimplikar, Director - Technical Operations, GMS- Merck Serono

Mr. Pramod Pimplikar, Director – Technical Operations, GMS- Merck Serono

Speaking on the occasion, Mr. Pramod Pimplikar, Director – Technical Operations, GMS- Merck Serono said, “We are extremely excited in being able to make a positive difference to our business, the environment and capacity building efforts. With this Green field site, we aim to reduce CO2 emission by 85% and deliver clean, green, efficient, reliable power and steam supply, improving efficiencies and contributing to the nation’s interest. By 2020 Merck KGaA has committed to reduce its global CO2 emissions by 20% and we are happy to be in a position to contribute to those efforts.”

The climate protection program Edison comprises around 300 climate protection and energy efficiency activities of the Merck Group. The objective is to reduce greenhouse gas emissions from energy generation as well as to enhance the energy efficiency of research and production processes. Merck aims to reduce its total direct and indirect greenhouse gas emissions by 20% by 2020, measured against the 2006 baseline. At its site in Jaffrey, New Hampshire (USA), Merck plans to commission a further biomass central heating plan next year.

Merck Groa Biomass Plant - Key Benefits

Merck is a leading company for innovative, top-quality high-tech products in the chemical, pharmaceutical and life science sectors. With its four divisions Merck Serono, Consumer Health, Performance Materials and Merck Millipore, Merck generated total revenues of around € 11.1 billion in 2013. Around 39,000 employees work for Merck in 66 countries to improve the quality of life for patients, to further the success of customers, and to help meet global challenges. Merck is the world’s oldest pharmaceutical and chemical company – since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70% interest, the founding family remains the majority owner of the company to this day. Merck, Darmstadt, Germany holds the global rights to the Merck name and brand. The only exceptions are Canada and the United States, where the company is known as EMD.

 
 

Tags: , , , , , , , , , , ,

Merck Advances to Sixth Place in the 2014 Access to Medicine Index

  • Merck moves up two places from previous rank 8
  • Access to Medicine Foundation acknowledges Merck’s strategic approach to access to health

Darmstadt, Germany, November 18, 2014 – Merck, a leading company for innovative and top-quality high-tech products in the pharmaceutical, chemical and life science sectors, announced today that it now ranks sixth in the Access to Medicine Index published yesterday by the Access to Medicine Foundation. Merck has moved up two places compared to the 2012 ranking. This improvement underlines the company’s commitment to helping overcome barriers to access for underserved populations and communities in low- and middle-income countries as part of its corporate responsibility and sustainable business approach. Every two years, the Access to Medicine Index benchmarks the top pharmaceutical companies on activities and initiatives that are advancing access to medicines in developing countries.

A2H_Praziquantel

“Merck has revised its Access to Health strategy and has launched new initiatives since 2012 including a pro-access business model in India and an innovative initiative to increase local manufacturing capabilities,” the Access to Medicine Foundation cited as reasons why Merck has advanced in the new ranking.

“Our efforts have been well-recognized by the Access to Medicine Foundation and we are proud to be ranked among the top leading companies only three years after starting our Access to Health initiative,” Stefan Oschmann, Chief Executive Officer Pharma and Vice Chairman Elect of the Executive Board of Merck, said. ”The fact that we’ve once again improved our ranking proves that access to health has become an integral part of how we conduct business. Of course we will continue our endeavors to better help patients, who are at the core of all our efforts, and to possibly further contribute to alleviating the various barriers to access for those most in need.”

Merck’s strategy to addressing the complex challenge of providing access to underserved populations and patients in low- and middle-income countries focuses upon four priority areas, known as the 4As for Availability, Affordability, Awareness and Accessibility. Whereas availability includes refining of health solutions to address unmet needs tailored to local environments, affordability entails addressing the inability to pay challenge. Awareness focuses on empowering people with appropriate tools and knowledge to make informed decisions, whether through education and training or metrics and evidence gathering, and accessibility comprises initiatives to strengthen supply chain and develop localized health solutions.

Compared to 2012, Merck now has been recognized by the Access to Medicine Foundation in particular for leading practices such as:

  • Strategic approach that comprises for example a strong focus on research & development for local and unmet needs and innovative manufacturing and distribution initiatives, including forward integration of supply chains
  • Multi-dimensional approach to fight the tropical worm disease schistosomiasis: a long-term donation program that aims to help eliminate the disease, as well as the development of a new diagnostic tool and a pediatric formulation
  • Pro-access IP management comprising of a commitment not to file for or enforce patents in the widest range of developing countries, access policies for future on-patent products, and open innovation initiatives
  • Merck established its Access to Health initiative in February 2011 and has identified access gaps and opportunities to better meet the needs of underserved patients. The unit is ensuring that access brings added value to the community at large, and is becoming an integral part of how Merck conducts business in a responsible, sustainable manner. Merck launched the Su-Swastha pilot program, a pro-access business model aiming at increasing access to healthcare products at an affordable price in rural India. Another example is the Merck Capacity Advancement Program (CAP) to raise awareness of diabetes in Africa and in India by educating the public and supporting the healthcare system on ways to prevent, diagnose and manage diabetes effectively. In summary, Merck recognizes the complexity of bringing health solutions to the poor and understands that Access to Medicine Index objectives cannot be reached by the pharmaceutical industry alone. Partnership, collaboration and continuous dialogue with a diverse array of stakeholders are key to ensuring that the delivery of sustainable access solutions is serving people’s needs.

Access to Medicine Foundation
The Access to Medicine Foundation is an international not for profit organization stimulating pharmaceutical companies to improve access to medicine to societies in need. Based in Haarlem, the Netherlands, the Foundation publishes the Access to Medicine Index, the first Index of its kind to rank pharmaceutical companies with respect to their efforts to enhance global access to medicine.

The Foundation aims to advance access to medicine in developing countries by encouraging the pharmaceutical industry to accept a greater role towards improving access to medicine in less developed countries. Please find more information here.

Access to Medicine Index
Access to medicines remains a very serious concern for billions of people suffering from disease and is still a primary challenge for the global health system. Reflecting the key role of the pharmaceutical industry in addressing the challenges of access, it is essential that the Access to Medicine Index’s approach to monitoring and evaluating the performance of the industry in this work is robust, balanced and comprehensive. The foundation every two years ranks 20 medium to large-size pharmaceutical companies with respect to their efforts to enhance global access to medicine. You can see the latest ranking as well as rankings from the past here.

All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to http://www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.

Merck is a leading company for innovative and top-quality high-tech products in the pharmaceutical, chemical and life science sectors. With its four divisions Merck Millipore, Merck Serono, Performance Materials and Consumer Health, Merck generated total revenues of € 11.1 billion in 2013. Around 39,000 Merck employees work in 66 countries to improve the quality of life for patients, to further the success of customers and to help meet global challenges. Merck is the world’s oldest pharmaceutical and chemical company – since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70% interest, the founding family remains the majority owner of the company to this day. Merck, Darmstadt, Germany is holding the global rights to the Merck name and brand. The only exceptions are Canada and the United States, where the company is known as Merck KGaA, Darmstadt, Germany.

 
Leave a comment

Posted by on November 19, 2014 in Merck Serono, Wellness

 

Tags: , ,

Merck Announces Global Strategic Alliance with Pfizer on Anti-PD-L1 to Accelerate Presence in Immuno-Oncology

  • Merck and Pfizer will jointly develop and commercialize Merck’s anti-PD-L1
  • Joint investment and combined strengths and capabilities will further maximize potential of Merck’s asset in the highly competitive anti-PD-1 / anti-PD-L1 space
  • Up to 20 high priority immuno-oncology clinical development programs expected to commence in 2015, including pivotal registration studies
  • Alliance accelerates Merck’s entry into the US oncology market

Darmstadt, Germany, November 17, 2014 – Merck (MRK GY) announced today that it has entered into a global agreement with Pfizer Inc. (NYSE:PFE) to co-develop and co-commercialize MSB0010718C, an investigational anti-PD-L1 antibody currently in development by Merck as a potential treatment for multiple tumor types to accelerate the two companies’ presence in immuno-oncology.

The asset will be developed as a single agent as well as in various combinations with Pfizer’s and Merck’s broad portfolio of approved and investigational pipeline candidates. The two companies will also combine resources and expertise to advance Pfizer’s anti-PD-1 antibody into Phase 1 trials. As part of the agreement, Merck will co-promote Pfizer’s XALKORI, a medicine to treat non-small cell lung cancer, in the United States and several other key markets.

e629723f-4073-4367-8e1f-66f6826f84e3-medium

Karl-Ludwig Kley, Chairman of Merck’s Executive Board stated: “We live up to our promise to strengthen all three pillars of our business: Healthcare, Performance Materials and Life Science. After this year’s acquisition of AZ Electronic Materials and the proposal to acquire Sigma-Aldrich, we have now turned the focus on healthcare. The agreement with Pfizer is a very important milestone in taking our pharma pipeline forward.”

“Collaborating globally with Pfizer will allow us to benefit from the strengths and capabilities of both companies in immuno-oncology, further accelerating this promising asset in the race to address the needs of cancer patients across multiple tumor types. Up to 20 high priority immuno-oncology clinical development programs are expected to commence in 2015, including pivotal registration studies,” continued Belén Garijo, President and Chief Executive Officer of Merck’s biopharmaceutical division Merck Serono and Executive Board Member Elect. “On top of that, the global alliance will enable Merck to gain an early entry into the US oncology market as well as to strengthen our existing oncology business in several other important global markets.”

There are currently two clinical development programs underway evaluating Merck’s anti-PD-L1 antibody. In a Phase 1 trial, more than 550 patients have been treated with MSB0010718C across multiple types of cancers. As part of the Analyst and Investor Day hosted by Merck on September 18, 2014, interim data were presented from the ongoing Phase 1 study demonstrating a complete response and partial responses in patients with non-small cell lung cancer and ovarian cancer. Additional data are expected to be presented at medical congresses in 2015. There is also an ongoing Phase 2 trial evaluating this antibody in patients with m-Merkel cell carcinoma, a rare form of skin cancer. For more information, please visit http://www.clinicaltrials.gov

Under the terms of the agreement, Merck will receive an upfront payment of $ 850 million (around € 680 million) and is eligible to receive regulatory and commercial milestone payments up to $ 2.0 billion. Both companies will jointly fund all development and commercialization costs and all revenues obtained from selling any anti-PD-L1 or anti-PD-1 products generated from this collaboration will be shared.

“Our strategic focus in the immuno-oncology space will be significantly enhanced through this global alliance, giving us the financial firepower to fully leverage the potential of our anti-PD-L1-compound” said Stefan Oschmann, Chief Executive Officer Pharma and Vice Chairman Elect of the Executive Board of Merck. “The success of the anti-PD-L1 program and the value recognised by Pfizer is a clear reflection of the progress we have made on our R&D pipeline in recent years.”

“This global alliance enables Pfizer and Merck to join forces and combine complementary strengths with the goal of meeting the needs of patients with multiple types of cancer,” said Albert Bourla, Group President Vaccines, Oncology and Consumer Healthcare Businesses, Pfizer. “Immuno-oncology is a top priority for Pfizer. Combining this promising anti-PD-L1 antibody with Pfizer’s extensive portfolio of small molecules and antibodies provides an opportunity to potentially broaden the use of immunotherapy for patients with cancer and rapidly expand our oncology business. In addition, this alliance enables us to significantly accelerate the time-frame of our development programs and move into the first wave of potential immuno-oncology based treatment regimens.”

All Merck news releases are distributed by e-mail at the same time they become available on the Merck website. Please go to http://www.merckgroup.com/newsabo to register online, change your selection or discontinue this service.
Merck is a leading company for innovative, top-quality high-tech products in the chemical and pharmaceutical sectors. With its four divisions Merck Serono, Consumer Health, Performance Materials and Merck Millipore, Merck generated total revenues of around € 11.1 billion in 2013. Around 39,000 employees work for Merck in 66 countries to improve the quality of life for patients, to further the success of customers, and to help meet global challenges. Merck is the world’s oldest pharmaceutical and chemical company – since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70% interest, the founding family remains the majority owner of the company to this day. Merck, Darmstadt, Germany is holding the global rights to the Merck name and brand. The only exceptions are Canada and the United States, where the company is known as EMD.

Cautionary Note Regarding Forward-Looking Statements
Certain statements made herein may be deemed to be solicitation materials in respect of the proposed acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany. The proposed acquisition will be submitted to the stockholders of Sigma-Aldrich for their consideration on December 5, 2014. In connection therewith, on November 3, 2014, Sigma-Aldrich filed a definitive proxy statement with the SECand began mailing the definitive proxy statement to its stockholders of record as of the close of business on October 29, 2014. BEFORE MAKING ANY VOTING OR ANY INVESTMENT DECISION, INVESTORS AND STOCKHOLDERS ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT REGARDING THE PROPOSED TRANSACTION AND ANY OTHER RELEVANT DOCUMENTS FILED OR TO BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION. Investors and stockholders may obtain free copies of the proxy statement, any amendments or supplements thereto and other documents containing important information about Sigma-Aldrich, once such documents are filed with the SEC, through the website maintained by the SEC at http://www.sec.gov. Copies of the documents filed with the SEC by Sigma-Aldrich will be available free of charge on Sigma-Aldrich’s website at http://investor.sigmaaldrich.com under the heading “Financial Information—SEC Filings”. Stockholders of Sigma-Aldrich may also obtain a free copy of the definitive proxy statement by contacting Sigma-Aldrich’s Investor Relations Department at (314) 898-4643.

Sigma-Aldrich and certain of its directors, executive officers and other members of management and employees may be deemed to be participants in the solicitation of proxies in connection with the proposed transaction. Information about the directors and executive officers of Sigma-Aldrich is set forth in its proxy statement for its 2014 annual meeting of stockholders, which was filed with the SEC on March 21, 2014, its annual report on Form 10-K for the fiscal year ended December 31, 2013, which was filed with the SEC on February 6, 2014, and in subsequent documents filed with the SEC, each of which can be obtained free of charge from the sources indicated above. Other information regarding the participants in the proxy solicitation of the stockholders of Sigma-Aldrich and a description of their direct and indirect interests, by share holdings or otherwise, is contained in the definitive proxy statement and other relevant materials filed with the SEC.

 
Leave a comment

Posted by on November 17, 2014 in Merck Serono

 

Tags: , , , , , , ,

Merck reports strong top-line growth in the 3rd Quarter 2014

1922309_881914215154739_3719811746879264206_nNovember 13, 2014 – Merck delivered strong sales growth of 9.3%, reporting sales of € 2.9 billion in the third quarter of 2014 (Q3 2013: € 2.7 billion). Owing to the good business performance in the first nine months and the very good organic sales growth in the third quarter, Merck is assuming slight organic sales growth for the full year 2014.

  • Sales increase by 9.3% in Q3
  • All regions on a growth course, Emerging Markets fuel growth further
  • EBITDA pre one-time items increases by 3.1% to € 857 million
  • Merck raises sales guidance and reiterates forecast for EBITDA pre one-time items for the full year 2014

 

 
Leave a comment

Posted by on November 13, 2014 in Industry, Merck Serono

 

Tags: , , , , , , ,

Merck Lends Support in the Fight Against Ebola

• Donation of € 250,000 made to the German Red Cross

Darmstadt, Germany, October 31, 2014 – Merck, a leading company for innovative and top-quality high-tech products in the pharmaceutical, chemical and life science sectors, will be donating € 250,000 to support the German Red Cross, a member of the International Federation of Red Cross and Red Crescent Societies, in the fight against Ebola. With this donation, the company is underlining social responsibility as part of its entrepreneurial approach.

ebola-virus-back-again134

“We want to help the people who are suffering in the affected countries quickly and in an uncomplicated manner. Therefore, we are providing the German Red Cross with € 250,000,” said Stefan Oschmann, CEO Pharma and Member of the Executive Board of Merck. “Our donation complements the many different initiatives with which Merck is helping to improve access to medicines and medical care for the people of Africa,” Oschmann added. The fight against the tropical worm disease schistosomiasis through donations of praziquantel tablets to the World Health Organization as well as efforts to contain the spread of counterfeit medicines through the use of mobile Minilabs represent two initiatives by Merck in this area.

“The entire provision of health care in Sierra Leone, Liberia and Guinea has virtually fallen apart. The conditions prevailing locally are catastrophic. We are therefore very happy to receive Merck’s contribution to the fight against Ebola,” said Rudolf Seiters, President of the German Red Cross. Local Red Cross aid workers have been in action since the outbreak of the epidemic in West Africa. The German Red Cross is supporting the national Red Cross organizations. In addition, the German Red Cross is expanding and enhancing a treatment center for Ebola patients operated by the International Red Cross in Sierra Leone. In Liberia, the German Red Cross will begin operating a treatment center for Ebola patients, with support from the German military, as of mid-November.

More information on the fight against Ebola can be found on the website of the International Federation of Red Cross and Red Crescent Societies.

All Merck Press Releases are distributed by e-mail at the same time they become available on the Merck Website. Please go to http://www.merckgroup.com/subscribe to register online, change your selection or discontinue this service.

Merck is a leading company for innovative and top-quality high-tech products in the pharmaceutical and chemical sectors. With its four divisions Merck Serono, Consumer Health, Performance Materials and Merck Millipore, Merck generated total revenues of € 11.1 billion in 2013. Around 39,000 Merck employees work in 66 countries to improve the quality of life for patients, to further the success of our customers and to help meet global challenges. Merck is the world’s oldest pharmaceutical and chemical company – since 1668, the company has stood for innovation, business success and responsible entrepreneurship. Holding an approximately 70% interest, the founding family remains the majority owner of the company to this day. Merck, Darmstadt, Germany is holding the global rights to the Merck name and brand. The only exceptions are Canada and the United States, where the company is known as EMD.

 
Leave a comment

Posted by on November 13, 2014 in Merck Serono

 

Tags: , , , , , ,

 
Follow

Get every new post delivered to your Inbox.

Join 64,566 other followers